#Clinical Trials

Articles (30)

• 🇺🇸 Verastem stock maintains Buy rating at BTIG on durable trial data — 10/04/2026 [USA] Related: #Biotechnology, #Financial Analysis
• 🇺🇸 Invivyd upsizes COVID-19 trial, targets measles antibody — 09/04/2026 [USA] Related: #Biotechnology, #Strategic Pivot
• 🇺🇸 Vanda initiates trial of NEREUS for GLP-1 therapy side effects — 08/04/2026 [USA] Related: #Pharmaceutical Innovation, #Market Strategy
• 🇺🇸 Lilly’s Taltz plus Zepbound shows efficacy in psoriatic arthritis trial — 28/03/2026 [USA] Related: #Pharmaceutical Innovation, #Psoriatic Arthritis Treatment, #Combination Therapy
• 🇺🇸 HUTCHMED begins phase III trial of HMPL-760 for lymphoma in China — 23/03/2026 [USA] Related: #Oncology
• 🇺🇸 IDEAYA delays darovasertib trial results to mid-April — 22/03/2026 [USA] Related: #Pharmaceutical Delays
• 🇺🇸 Aelis Farma begins recruiting for Down syndrome drug trial — 21/03/2026 [USA] Related: #Down Syndrome
• 🇺🇸 Eli Lilly’s next-generation obesity drug retatrutide clears first late-stage diabetes trial — 19/03/2026 [USA]

  Lilly is betting big on retatrutide as the next pillar of its obesity portfolio after its weight loss injection Zepbound and its upcoming pill, orforglipron.

  Related: #Pharmaceuticals
• 🇺🇸 Vaxcyte publishes VAX-31 phase 1/2 study results in Lancet — 18/03/2026 [USA] Related: #Vaccine Development
• 🇺🇸 MetaVia receives IRB approval for Phase 1 Part 3 trial of DA-1726 — 18/03/2026 [USA] Related: #Regulatory Approval
• 🇺🇸 Medicus Pharma to host fireside chat on SkinJect trial results — 18/03/2026 [USA] Related: #Pharmaceuticals
• 🇺🇸 InflaRx to present Phase 3 pyoderma gangrenosum data at AAD — 18/03/2026 [USA] Related: #Dermatology
• 🇺🇸 OKYO Pharma reports quality of life improvements in pain trial — 18/03/2026 [USA] Related: #Pain Management
• 🇺🇸 AtaiBeckley publishes Phase 2a data for depression treatment — 17/03/2026 [USA] Related: #Mental Health
• 🇺🇸 Citizens reiterates Lyell Immunopharma stock rating on trial progress — 16/03/2026 [USA] Related: #Stock Rating
• 🇺🇸 Jefferies downgrades Summit Therapeutics stock rating on trial risks — 16/03/2026 [USA] Related: #Stock Downgrade
• 🇺🇸 Acurx Pharmaceuticals stock gains over 3% on new rCDI trial launch — 13/03/2026 [USA] Related: #Biopharmaceuticals, #Stock Performance
• 🇺🇸 Chardan reiterates Orchestra BioMed stock rating on trial focus — 12/03/2026 [USA] Related: #Stock Analysis
• 🇺🇸 Ultragenyx reports positive Phase 3 data for OTC gene therapy — 12/03/2026 [USA] Related: #Gene Therapy, #Rare Diseases
• 🇺🇸 Oppenheimer reiterates Sagimet stock rating on MASH trial progress — 11/03/2026 [USA] Related: #Biotech Investment
• 🇺🇸 BridgeBio presents positive interim data for LGMD2I/R9 therapy — 11/03/2026 [USA] Related: #Rare Disease Treatment
• 🇺🇸 Moleculin Biotech releases CEO update on leukemia trial — 11/03/2026 [USA] Related: #Biotechnology, #Leukemia
• 🇺🇸 Celcuity at Leerink Conference: Promising Breast Cancer Drug Results — 10/03/2026 [USA] Related: #Oncology
• 🇺🇸 Aptevo Therapeutics stock tumbles despite positive trial data — 10/03/2026 [USA] Related: #Stock Performance
• 🇺🇸 Raymond James upgrades Dianthus stock on CIDP trial results — 10/03/2026 [USA] Related: #Stock Upgrade
• 🇺🇸 Ondine Biomedical reports 93% enrollment in Phase 3 infection study — 10/03/2026 [USA] Related: #Biotechnology
• 🇺🇸 Telix prostate cancer drug trial meets safety goals — 09/03/2026 [USA] Related: #Oncology
• 🇺🇸 Biofrontera reports Phase 2b acne trial results for Ameluz PDT — 09/03/2026 [USA] Related: #Dermatology
• 🇺🇸 Dyne Therapeutics launches phase 3 trial for DM1 treatment — 08/03/2026 [USA] Related: #Genetic Medicine
• 🇺🇸 Xenon Pharmaceuticals to report epilepsy drug trial results Monday — 08/03/2026 [USA] Related: #Pharmaceuticals